CHICAGO—The present-day standard CHOP-rituximab regimen for all indolent lymphomas has been overturned according to German investigators reporting here to the annual meeting of the American Society of Clinical Oncology. Professor Mathias Rummel of Giessen University gave Peter Goodwin his latest findings which he recommends should change practice.
Indolent Lymphoma Standard Therapy Needs To Change: Bendamustine-Rituximab: Better Than CHOP-Rituximab
Further reading
Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Audio Journal of Oncology Podcast Ultrahypofractionated Radiation Just As Effective for Prostate Cancer Play Episode Pause Episode Mute/Unmute...
PHILADELPHIA, USA—For the first time researchers have succeeded in making small number of patients with AIDS more resistant to HIV by infusing them...
STOCKHOLM, SWEDEN—A study in JAMA Anti-coagulation has reported that warfarin could be beneficial for patients with atrial fibrillation (AF) even if...
CINCINNATI, USA—A link has been demonstrated for the first time between prostate cancer and exposure to the synthetic compound bisphenol-A (BPA ) —...